Read by QxMD icon Read

Onabotulinum toxin A

Justin R Shinn, Nkechi N Nwabueze, Liping Du, Priyesh N Patel, Kevin K Motamedi, Cathey Norton, William R Ries, Scott J Stephan
Importance: In the last decade, there has been a significant increase in the number of practitioners administering botulinum toxin for facial synkinesis. However, there are few resources available to guide treatment patterns, and little is known about how these patterns are associated with functional outcomes and quality of life. Objective: To evaluate botulinum treatment patterns, including the dosing and frequency of muscle targeting, for treatment of facial synkinesis and to quantify patient outcomes...
January 31, 2019: JAMA Facial Plastic Surgery
Karen A Williams, Robin M Lawson, Osvaldo H Perurena, John D Coppin
Introduction: The rate of chronic migraine (CM) has been shown to be 20% or greater in the post 9/11 combat veteran population with a history of traumatic brain injury, while the rate is much lower at 3-5% in the general population. Studies have shown that medications such as oral topiramate or intramuscular injections of onabotulinum toxin A (Botox) have been used for CM prevention, and occipital blocks have been shown to be helpful in treating occipital neuralgia and short-term relief of CM...
January 23, 2019: Military Medicine
Jae Eun Choi, Tyler Werbel, Zhenping Wang, Chia Chi Wu, Tony L Yaksh, Anna Di Nardo
BACKGROUND: Rosacea is a chronic inflammatory skin condition whose etiology has been linked to mast cells and the antimicrobial peptide cathelicidin LL-37. Individuals with refractory disease have demonstrated clinical benefit with periodic injections of onabotulinum toxin, but the mechanism of action is unknown. OBJECTIVES: To investigate the molecular mechanism by which botulinum toxin improves rosacea lesions. METHODS: Primary human and murine mast cells were pretreated with onabotulinum toxin A or B or control...
December 28, 2018: Journal of Dermatological Science
William B Young
No abstract text is available yet for this article.
January 2019: Headache
Hyun Young Lee, Seung Whan Doo, Won Jae Yang, Yun Seob Song, Hwa Yeon Sun, Eli Jongchan Nho, Bora Lee, Jae Heon Kim
OBJECTIVE: To investigate the efficacy and safety of noninvasive intravesical instillation of onabotulinum toxin-A (OBTX-A) through systematic review and meta-analysis. Recently, several studies of noninvasive intravesical instillation of OBTX-A have been published. However, its efficacy is not well validated yet compared to well-known efficacy of minimally invasive intravesical injection of OBTX-A. METHOD: Systematic review and meta-analysis were performed to evaluate the efficacy of noninvasive intravesical instillation of OBTX-A in patients with overactive bladder and interstitial cystitis/bladder pain syndrome by measuring outcomes such as urgency episode per 72 hours, frequency per 72 hours, urgency urinary incontinence, voided volume (VV), postvoided residual volume, maximum flow rate, and patient perception of bladder condition...
December 12, 2018: Urology
Anupam Datta Gupta, Graeme Tucker, Simon Koblar, Renuka Visvanathan, Ian D Cameron
Foot dystonia (FD) is a disabling condition causing pain, spasm and difficulty in walking. We treated fourteen (14) adult patients experiencing FD with onabotulinum toxin A injection into the dystonic foot muscles. We analyzed the spatiotemporal gait utilizing the GaitRite system pre- and 3 weeks post-botulinum toxin injection along with measuring dystonia by the Fahn⁻Marsden Dystonia Scale (FMDS), pain by the Visual Analog Scale (VAS) and other lower limb functional outcomes such as gait velocity, the Berg Balance Scale (BBS), the Unified Parkinson's Disease Rating Scale⁻Lower Limb Score (UPDRS⁻LL), the Timed Up and Go (TUG) test and the Goal Attainment Scale (GAS)...
December 12, 2018: Toxins
Jason L Weller, Douglas Comeau, James A D Otis
Myofascial pain syndromes arise from acute and chronic musculoskeletal pain and often have a referred neuropathic component. It affects more than three quarters of the world's population and is one of the most important and overlooked causes of disability. The origins of pain are thought to reside anywhere between the motor end plate and the fibrous outer covering of the muscle, with involvement of microvasculature and neurotransmitters at the cellular level. Diagnosis is made by clinical examination for the presence of myofascial trigger points, though some ancillary tests may provide supportive evidence...
December 2018: Seminars in Neurology
Hannah Aura Shoval, Esther Antelis, Andrew Hillman, Xiaofang Wei, Patricia Tan, Ruth Alejandro, Heakyung Kim
OBJECTIVE: The aim of the study was to investigate the safety and efficacy of onabotulinum toxin A injection to the salivary glands under ultrasound guidance for the treatment of sialorrhea in patients with spinal muscular atrophy type I. DESIGN: Prospective case series with four patients with spinal muscular atrophy type I who received onabotulinum toxin A injection to parotid and submandibular glands for sialorrhea as part of clinical care. All four patients received validated surveys for measuring drooling, including objective measures of number of bib changes, and number of mouth wipes before injection and 4-6 wks after injection...
December 2018: American Journal of Physical Medicine & Rehabilitation
Sandra Mühlstädt, Shahidul Mischner, Jennifer Kranz, Petra Anheuser, Nasreldin Mohammed, Joachim A Steffens, Paolo Fornara
Background: Idiopathic overactive bladder (iOAB), with or without urge incontinence (UI), has significant psychosocial effects on patients' quality of life (QoL). The first choice of treatment for iOAB is anticholinergics and, alternatively, the β-3-adrenoceptor agonist mirabegron. However, systemic side effects and contraindications should be considered for both medications. Objective: We report the efficacy, safety and effects on QoL of botulinum toxin therapy (onabotulinum toxin type A, BOTOX®, Allergan) among patients with iOAB ± UI...
2018: Frontiers in Surgery
Natalie A Krane, Jeffrey D Markey, Myriam Loyo
INTRODUCTION: Congenital unilateral lower lip palsy is an infrequently encountered condition that manifests as lower lip asymmetry during smiling, laughing, and crying. Treatment options are not well characterized. METHODS: The authors present the case of a 51-year-old woman who was referred for surgical intervention for facial paralysis. Physical examination demonstrated a symmetric face at rest that became asymmetric when smiling. The asymmetry, evident by inappropriate inferior displacement of the lower lip, was secondary to unilateral contraction and presence of the depressor labii inferioris...
October 22, 2018: Annals of Otology, Rhinology, and Laryngology
Toren P Stearns, Mujeeb U Shad, Gabriela C Guzman
Objective: To provide a critical appraisal of the primary clinical trials exploring the use of glabellar botulinum toxin type A (BTA) injections in the treatment of major depressive disorder (MDD) and propose future directions for research on this topic. Data Sources: A search in PubMed, Scopus, and Google Scholar databases was performed in September 2017. Search terms included ("botulinum" OR "botox" OR "abobotulinumtoxin" OR "onabotulinum" OR "onabotulinumtoxin" OR "botulinumtoxin") AND ("antidepressant" OR "depression" OR "depressive" OR "depressed")...
October 4, 2018: Primary Care Companion to CNS Disorders
Riccardo Lombardo, Karl-Erik Andersson, Andrea Tubaro, Cosimo De Nunzio
BACKROUND: Endoscopic surgical treatment represents the gold standard in patients with lower urinary tract symptoms (LUTS) when medical treatment fails. In the past years there has been a growing interest in intra-prostatic injections which represent a minimally invasive alternative for those patients not suitable for surgery. Aim of our study is to systematically review all the available data on intra-prostatic injections for the treatment of LUTS patients with benign prostatic enlargement (BPE)...
October 3, 2018: Minerva Urologica e Nefrologica, the Italian Journal of Urology and Nephrology
Vikram M Narayan, Joseph J Pariser, Ronak A Gor, Jenna Katorski, Sean P Elliott
AIMS: Cerebral palsy (CP) is characterized by motor impairments as a result of brain injury during development. Patients can have neurogenic bladder dysfunction and are often unable to catheterize through their native urethra. Catheterizable channel (CC) creation can facilitate clean intermittent catheterization (CIC). We have observed that patients with large capacity, low-pressure bladders can develop de novo neurogenic detrusor overactivity (NDO) postoperatively. We sought to better characterize this finding...
September 24, 2018: Neurourology and Urodynamics
Giorgio Ivan Russo, Uros Milenkovic, Wayne Hellstrom, Laurence A Levine, David Ralph, Maarten Albersen
CONTEXT: Conservative therapies for Peyronie's disease (PD) aim to treat early-stage disease by improving clinical outcomes such as penile curvature, penile length erectile dysfunction, and pain. OBJECTIVE: To summarise the available evidence regarding injection and mechanical therapies for PD treatment. EVIDENCE ACQUISITION: An extensive search of Medline, Embase, and Scopus databases retrieved English-language articles up to 15 May 2018...
December 2018: European Urology
Christine M Alvarez, James G Wright, Harpreet Chhina, Alyssa Howren, Peggy Law
BACKGROUND: Congenital idiopathic clubfoot is a condition that affects, on average, approximately 1 in 1,000 infants. One broadly adopted method of management, described by Ponseti, is the performance of a percutaneous complete tenotomy when hindfoot stall occurs. The use of onabotulinum toxin A (BTX-A) along with the manipulation and cast protocol described by Ponseti has been previously reported. Our goal was to compare the clinical outcomes between BTX-A and placebo injections into the gastrocnemius-soleus muscle at the time of hindfoot stall in infants with idiopathic clubfoot treated with the Ponseti method of manipulation and cast changes...
September 19, 2018: Journal of Bone and Joint Surgery. American Volume
Syed Imran Raza, Ashkan Heshmatzadeh Behzadi, Jon D Blumenfeld, Sarah K Girardi, Martin R Prince
Urinary incontinence due to neurogenic detrusor overactivity is common in patients with disorders of lower motor neurons controlling the bladder. Multiple sclerosis is a major cause of neurogenic detrusor overactivity, which negatively impacts quality of life. Bladder wall injection of onabotulinum toxin A can diminish spontaneous bladder contraction, urinary urgency, and urge incontinence. Herein we report a 61-year-old woman with multiple sclerosis and autosomal dominant polycystic kidney disease with bladder trabeculation developing after repeated injections of onabotulinum toxin A...
October 2018: Radiology Case Reports
J Ingham, R Angotti, M Lewis, A Goyal
INTRODUCTION: Botulinum toxin-A (BtA) has been used for refractory idiopathic overactive bladder (IOAB) in children. Data on the optimum dose success rates, duration of effect, complications and medium-term outcomes are limited. This study aims to analyse the authors' experience to provide medium-term results of BtA in symptomatic refractory patients. MATERIALS AND METHODS: Patients with refractory IOAB who were treated with BtA (Botox®) were retrospectively analysed...
August 16, 2018: Journal of Pediatric Urology
Irina Aschehoug, Daniel Fossum Bratbak, Erling Andreas Tronvik
OBJECTIVES: To investigate long-term outcomes in per-protocol chronic cluster headache patients (n = 7), 18 and 24 months after participation in "Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic cluster headache." METHODS: Data were collected prospectively through headache diaries, HIT-6, and open questionnaire forms at 18 and 24 months after the first treatment. Patients had access to repeated injections when needed...
November 2018: Headache
A Doherty, D B Hennessey, J R Onggo, W Ranasinghe, J Gani
PURPOSE: One quarter of patients will not respond to initial intra-detrusor Botulinum toxin A (BTX) injections for detrusor overactivity. Alternative treatment options include long-term catheterization, sacral neuromodulation, urinary diversion or bladder augmentation. Some of these procedures are invasive. This review explores modifications to BTX delivery that can improve outcome. METHODS: A search of Medline, Embase and Cochrane Library to December 2017 was performed according to Preferred Reporting Items for Systematic Review and Metaanalysis (PRISMA) guidelines...
August 23, 2018: World Journal of Urology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"